Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma.

Immuno-oncology technology·2025
Same author

Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer.

Cancer gene therapy·2023
Same author

Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine.

Cancer gene therapy·2023
Same author

Low incidence of severe bacterial infections in hospitalised patients with COVID-19: A population-based registry study.

Infectious diseases (London, England)·2022
Same author

COVID-19 cases in spectators returning to Finland from UEFA Euro 2020 matches in Saint Petersburg.

Epidemiology and infection·2022
Same author

Detection of SARS-CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection.

Journal of virological methods·2022

Related Experiment Video

Updated: Jun 5, 2026

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

Oncolytic adenovirus based on serotype 3.

O Hemminki1, G Bauerschmitz, S Hemmi

  • 1Cancer Gene Therapy Group, Molecular Cancer Biology Program and Haartman Institute and Transplantation Laboratory and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland.

Cancer Gene Therapy
|December 25, 2010
PubMed
Summary

A novel serotype 3 oncolytic adenovirus, Ad3-hTERT-E1A, shows promise for cancer treatment. This virus maintains efficacy even with pre-existing anti-adenovirus type 5 antibodies, potentially enabling repeated dosing.

More Related Videos

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Related Experiment Videos

Last Updated: Jun 5, 2026

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Area of Science:

  • Oncolytic virotherapy
  • Viral oncology
  • Gene therapy

Background:

  • Oncolytic adenoviruses, primarily serotype 5 based, show limited efficacy in clinical trials due to variable receptor expression in tumors.
  • Pre-existing neutralizing antibodies against adenovirus serotype 5 can hinder treatment efficacy and limit re-administration.
  • Adenovirus serotype 3 receptors are broadly expressed in tumors, suggesting potential for improved oncolytic adenovirus targeting.

Purpose of the Study:

  • To develop and evaluate a fully serotype 3 oncolytic adenovirus (Ad3-hTERT-E1A) for cancer treatment.
  • To assess the efficacy of Ad3-hTERT-E1A in vitro and in vivo, particularly in the presence of anti-adenovirus type 5 antibodies.
  • To explore the potential of serotype 3 adenoviruses for overcoming limitations associated with serotype 5 based oncolytic viruses.

Main Methods:

  • Construction of Ad3-hTERT-E1A, a serotype 3 oncolytic adenovirus utilizing the human telomerase promoter.
  • In vitro efficacy testing on cancer cell lines representing seven major cancer types and assessment of toxicity in non-malignant cells.
  • In vivo anti-tumor efficacy evaluation in three distinct animal models and comparison with serotype 5 based controls in the presence of neutralizing antibodies.

Main Results:

  • Ad3-hTERT-E1A demonstrated in vitro efficacy across multiple cancer types with low toxicity in normal cells.
  • The virus exhibited significant anti-tumor efficacy in vivo across three animal models.
  • Ad3-hTERT-E1A retained anti-tumor activity in the presence of anti-adenovirus type 5 neutralizing antibodies, unlike serotype 5 based controls.

Conclusions:

  • A fully serotype 3 oncolytic adenovirus (Ad3-hTERT-E1A) has been successfully generated.
  • This novel oncolytic adenovirus shows potential for treating various cancers, especially in patients with high levels of anti-adenovirus type 5 antibodies.
  • The development of Ad3-hTERT-E1A offers a promising alternative for oncolytic virotherapy, potentially facilitating repeated dosing strategies.